Does dapsone-mediated activation of flurbiprofen metabolism by CYP2C9 occur in vivo?

被引：0
|
作者：
Hutzler, JM
Frye, RF
Korzekwa, KR
Branch, RA
Huang, SM
Tracy, TS
机构：
[1] US FDA, Rockville, MD 20857 USA
[2] Univ Pittsburgh, Ctr Clin Pharmacol, Pittsburgh, PA USA
[3] W Virginia Univ, Sch Pharm, Morgantown, WV 26506 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2000年 / 67卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII78
引用
收藏
页码：134 / 134
页数：1
相关论文
共 50 条
  • [21] Application of Vivid™ fluorogenic substrates for the in vitro assessment of CYP2C9*1, CYP2C9*2 and CYP2C9*3 metabolism
    Thompson, DV
    Marks, BD
    Goossens, TA
    Trubetskoy, OV
    DRUG METABOLISM REVIEWS, 2002, 34 : 153 - 153
  • [22] Functional impact of CYP2C*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans
    Allabi, AC
    Gala, JL
    Horsmans, Y
    Babaoglu, MO
    Bozkurt, A
    Heusterspreute, M
    Yasar, U
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (02) : 113 - 118
  • [23] CYP2C9 active site determinants of phenytoin metabolism, orientation, and lansoprazole-mediated activation
    Mosher, Carrie M.
    Rettie, Allan E.
    DRUG METABOLISM REVIEWS, 2006, 38 : 73 - 74
  • [24] Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans
    Lee, CR
    Pieper, JA
    Frye, RF
    Hinderliter, AL
    Blaisdell, JA
    Goldstein, JA
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (01): : 84 - 91
  • [25] Dapsone activation of CYP2C9-mediated metabolism: Evidence for activation of multiple substrates and a two-site model
    Hutzler, JM
    Hauer, MJ
    Tracy, TS
    DRUG METABOLISM AND DISPOSITION, 2001, 29 (07) : 1029 - 1034
  • [26] Does celecoxib inhibit agomelatine metabolism via CYP2C9 or CYP1A2?
    Yasar, Umit
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 2169 - 2170
  • [27] CYP2C9 polymorphisms and CYP2C9*2 genotyping primers
    Goldstein, JA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) : 409 - 410
  • [28] High-throughput screening assays for the assessment of CYP2C9*1, CYP2C9*2, and CYP2C9*3 metabolism using fluorogenic Vivid® substrates
    Marks, BD
    Thompson, DV
    Goossens, TA
    Trubetskoy, OV
    JOURNAL OF BIOMOLECULAR SCREENING, 2004, 9 (05) : 439 - 449
  • [29] Echinacea alters CYP2C9 activity in vivo
    Gorski, JC
    Huang, SM
    Pinto, A
    Miller, P
    Desai, M
    Hall, SD
    DRUG METABOLISM REVIEWS, 2002, 34 : 131 - 131
  • [30] Effect of iguratimod on diclofenac metabolism by CYP2C9 in rats and human recombinant CYP2C9 yeast cells
    Usman, Muhammad
    Zhen-Han, Zhu
    Ze-Na, Chang
    Jun-Ping, Han
    Wen, Qian
    Chang-Qing, Yang
    Miyu, Nishikawa
    Toshiyuki, Sakaki
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 55
12345